Renata PLC has launched Cabergoline 0.5mg tablets in France and the Nordic countries, marking a significant step in its international expansion strategy.

The product, used primarily to treat hyperprolactinemic disorders and also prescribed for Parkinson’s disease, is manufactured at Renata’s EU GMP-certified facility. The certification affirms the plant’s compliance with European Union Good Manufacturing Practice standards, a key requirement for marketing medicines in Europe.

Cabergoline is a dopamine receptor agonist that lowers elevated prolactin levels. Hyperprolactinemic disorders can result in a range of health complications, including menstrual irregularities and infertility. The medicine is already available in Bangladesh under the brand name Cabolin.

This launch follows Renata’s earlier entry into the UK market with the same product—an achievement considered pivotal for any pharmaceutical firm aiming for recognition in highly regulated territories. The simultaneous rollout in France and the Nordic countries further extends the company’s footprint in Europe.

In a press release, Renata highlighted the development as part of its broader goal to position itself as a global pharmaceutical manufacturer. By targeting specialised therapeutic areas, the company aims to contribute to expanding access to essential medicines beyond its domestic market.